3:48 PM
 | 
Dec 06, 2017
 |  BC Extra  |  Clinical News

Madrigal gains on NASH data

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) jumped $40.88 (88%) to $87.18 on Wednesday after reporting that MGL-3196 (VIA-3196) met the primary endpoint in a Phase II trial to treat biopsy-proven non-alcoholic steatohepatitis.

On the 125-patient trial's primary endpoint, once-daily oral MGL-3196 significantly...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >